May 23, 2007

Securities and Exchange Commission
100 F Street, NE
Washington, D.C.
20549

Filed: EDGAR/CORRESP


Dear Sirs and Mesdames,

Re:     Comment Letter, dated March 30, 2007 related to
Form 20-F for fiscal year ended May 31, 2006 (the “Comment Letter”) File No. 001-32001


Lorus Therapeutics Inc. hereby notifies the Securities and Exchange Commission that it currently expects to provide responses to the comments contained in the Comment Letter on or before June 15, 2007.



Sincerely,

/s/ Mark Preston

Mark Preston,
Acting Controller
 
 
 

 
LORUS THERAPEUTICS INC.
2 Meridian Road
Toronto, Ontario
M9W 4Z7
T: 416.798.1200
F: 416.798.2200
www.lorusthera.com
info@lorusthera.com